Diamyd Medical’s manufacturing process may be moved to a new manufacturer
Diamyd Medical AB announces that its manufacturing process of rhGAD65, the active ingredient in the diabetes vaccine Diamyd®, may be moved to a new manufacturer.Diamyd Medical’s CEO Ulf Hannelius and its founder Anders Essen-Moller report that - at a meeting in New York with Protein Sciences Corporation - they were informed that Protein Sciences will not be able to meet Diamyd Medical’s manufacturing needs for rhGAD65 as per a Purchase Agreement Order of August 8, 2017, that was issued under the Development and Commercial Supply Agreement of July 12, 2008. Protein Sciences has offered to